SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's surges on launching Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection

25 Sep 2020 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 5118.05, up by 93.60 points or 1.86% from its previous closing of Rs. 5024.45 on the BSE.

The scrip opened at Rs. 5130.00 and has touched a high and low of Rs. 5150.00 and Rs. 5060.00 respectively. So far 71654 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 2497.60 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 5514.65 and Rs. 5000.00  respectively. The current market cap of the company is Rs. 84685.10 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.

Dr. Reddy's Laboratories has launched Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Precedex in 0.9% Sodium Chloride Injection brand and generic market had U.S. sales of approximately $210 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.

Dr. Reddy’s Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively. The strength is based on the dexmedetomidine base. Containers are intended for single-dose only.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1286.55 15.60 (1.23%)
06-May-2026 11:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1846.30
Dr. Reddys Lab 1286.55
Cipla 1352.10
Zydus Lifesciences 937.60
Lupin 2419.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×